HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Clinical impact of the new IASLC/ATS/ERS lung adenocarcinoma classification for chest surgeons.

Abstract
In 2011, a new pathological classification of lung adenocarcinoma was proposed by the International Association for the Study of Lung Cancer, the American Thoracic Society and the European Respiratory Society. The new criteria classify adenocarcinomas into eight subtypes according to their histological features. The criteria introduce a new concept of early stage lung cancer, consisting of adenocarcinoma in situ and minimally invasive adenocarcinoma, and categorize invasive adenocarcinomas by the predominant histological pattern. In addition to morphological differences among subtypes, the classification also considers the tumor behavior based on the genetic background within each subtype. We herein review the clinical impact of this new classification for chest surgeons based on the data from several recent validation studies from various institutions.
AuthorsHaruhiko Nakamura, Masayuki Takagi
JournalSurgery today (Surg Today) Vol. 45 Issue 11 Pg. 1341-51 (Nov 2015) ISSN: 1436-2813 [Electronic] Japan
PMID25417186 (Publication Type: Journal Article, Review)
Topics
  • Adenocarcinoma (pathology, surgery)
  • Adenocarcinoma of Lung
  • Humans
  • Lung Neoplasms (pathology, surgery)
  • Prognosis
  • Surgeons
  • Survival Rate
  • Thoracic Surgery
  • Thoracic Surgical Procedures (mortality)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: